HOME
ABOUT US
OUR COMPANY
OUR TEAM
BOARD OF DIRECTORS
INVESTORS
CAREERS
T-GUARD®
CHARACTERISTICS
DEVELOPMENT PLAN
GRAFT-VERSUS-HOST
ADDITIONAL INDICATIONS
EXPANDED ACCESS
A PATIENT’S STORY
NEWS & EVENTS
NEWS
EVENTS
IN THE MEDIA
PARTNERING
PARTNERING FOR PROGRESS
CONTACT
NEWS
18 december 2019
Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial
3 december 2019
Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting
2 december 2019
Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer
14 oktober 2019
Xenikos receives FDA Fast Track designation for T-Guard® for treating steroid-refractory acute graft-versus-host disease
11 juni 2019
Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD
20 december 2018
Xenikos partners with the BMT CTN to conduct a U.S.-based Phase 3 trial to test T-Guard® in aGVHD
16 november 2018
Final results from T-Guard® Phase 1/2 trial in steroid-resistant aGVHD published in journal BBMT
14 mei 2018
Dutch Company Xenikos Secures USD 30 Million in Series B Financing
11 december 2017
Data from phase 1/2 trial with T‑Guard® presented at ASH Annual Meeting
Load more
